Organization
Pharmacyclics LLC
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Pharmacyclics LLC
... evidence began to suggest a lower dose might be effective, Janssen and Pharmacyclics announced they were discontinuing the old capsule and introducing once-a-day tablets in ...
... evidence began to suggest a lower dose might be effective, Janssen and Pharmacyclics announced they were discontinuing the old capsule and introducing once-a-day tablets in ...
... Society and CLL Patient; and Lori Kunkel, MD, Former Chief Medical Officer, Pharmacyclics. These leading experts in hematologic malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma ...
... money. Then they learned of a new pricing strategy by Janssen and Pharmacyclics, the companies that sell Imbruvica through a partnership. Within the next three ...
... knows those dynamics well: As chief of oncology operations and alliances at Pharmacyclics, she guided the blood cancer drug Imbruvica through development before the smaller ...
... off a big buyout. “Very few investors saw its 2015 purchase of Pharmacyclics for $21 billion coming either,” he noted. RELATED: AbbVie paid a 'lofty,' ...
... a first-in-class Bruton's tyrosine kinase (BTK) inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. 'These new data further ...
... (BTK) inhibitor, is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. 'Data from this large clinical trial data set ...
... a first-in-class Bruton's tyrosine kinase (BTK) inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. "In the RESONATE-2 study, ...
... kinase (BTK) inhibitor jointly developed and commercialized by Janssen Biotech, Inc., and Pharmacyclics LLC, an AbbVie company. "It is gratifying to see that patients with ...
Subscribe now for full coverage on Pharmacyclics LLC
Start My Free Trial